These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 33544561)
1. Mediterranean, vegetarian and vegan diets as practical outtakes of EAS and ACC/AHA recommendations for lowering lipid profile. Wojda A; Janczy A; Małgorzewicz S Acta Biochim Pol; 2021 Feb; 68(1):41-48. PubMed ID: 33544561 [TBL] [Abstract][Full Text] [Related]
2. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708 [TBL] [Abstract][Full Text] [Related]
3. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Ray KK; Kastelein JJ; Boekholdt SM; Nicholls SJ; Khaw KT; Ballantyne CM; Catapano AL; Reiner Ž; Lüscher TF Eur Heart J; 2014 Apr; 35(15):960-8. PubMed ID: 24639424 [TBL] [Abstract][Full Text] [Related]
4. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI. Vallejo-Vaz AJ; Bray S; Villa G; Brandts J; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Kees Hovingh G; Jozwiak JJ; Jukema JW; Gabor Kiss R; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR; Ray KK; Cardiovasc Drugs Ther; 2023 Oct; 37(5):941-953. PubMed ID: 35567726 [TBL] [Abstract][Full Text] [Related]
5. New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC/AHA and 2019 ESC/EAS Guidelines. Raygor V; Khera A Curr Cardiol Rep; 2020 Jul; 22(9):87. PubMed ID: 32647997 [TBL] [Abstract][Full Text] [Related]
6. The Role of Specific Components of a Plant-Based Diet in Management of Dyslipidemia and the Impact on Cardiovascular Risk. Trautwein EA; McKay S Nutrients; 2020 Sep; 12(9):. PubMed ID: 32883047 [TBL] [Abstract][Full Text] [Related]
7. Diet and Nutraceutical Supplementation in Dyslipidemic Patients: First Results of an Italian Single Center Real-World Retrospective Analysis. Pasta A; Formisano E; Cremonini AL; Maganza E; Parodi E; Piras S; Pisciotta L Nutrients; 2020 Jul; 12(7):. PubMed ID: 32664400 [TBL] [Abstract][Full Text] [Related]
8. Nutrition and physical activity recommendations from the United States and European cardiovascular guidelines: a comparative review. Ferraro RA; Fischer NM; Xun H; Michos ED Curr Opin Cardiol; 2020 Sep; 35(5):508-516. PubMed ID: 32649350 [TBL] [Abstract][Full Text] [Related]
9. Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction. Sikand G; Severson T Am J Prev Cardiol; 2020 Dec; 4():100106. PubMed ID: 34327475 [TBL] [Abstract][Full Text] [Related]
10. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620 [TBL] [Abstract][Full Text] [Related]
11. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Qureshi WT; Kaplan RC; Swett K; Burke G; Daviglus M; Jung M; Talavera GA; Chirinos DA; Reina SA; Davis S; Rodriguez CJ J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28495699 [TBL] [Abstract][Full Text] [Related]
12. Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. Lee JC; Zdrojewski T; Pencina MJ; Wyszomirski A; Lachacz M; Opolski G; Bandosz P; Rutkowski M; Gaciong Z; Wyrzykowski B; Navar AM JAMA Cardiol; 2016 Sep; 1(6):700-7. PubMed ID: 27434662 [TBL] [Abstract][Full Text] [Related]
13. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond. Waite LH; Phan YL; Spinler SA J Am Pharm Assoc (2003); 2016; 56(3):284-92. PubMed ID: 27156942 [TBL] [Abstract][Full Text] [Related]
14. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients. Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797 [TBL] [Abstract][Full Text] [Related]
15. New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia. Adhyaru BB; Jacobson TA Cardiol Clin; 2015 May; 33(2):181-96. PubMed ID: 25939292 [TBL] [Abstract][Full Text] [Related]
16. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias]. Catapano AL; Averna M; Faggiano P; Novo S G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730 [No Abstract] [Full Text] [Related]
17. Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines. Singh M; McEvoy JW; Khan SU; Wood DA; Graham IM; Blumenthal RS; Mishra AK; Michos ED Mayo Clin Proc; 2020 May; 95(5):998-1014. PubMed ID: 32370858 [TBL] [Abstract][Full Text] [Related]
18. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038 [TBL] [Abstract][Full Text] [Related]
19. Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA). Flueckiger P; Qureshi W; Michos ED; Blaha M; Burke G; Sandfort V; Herrington D; Yeboah J Clin Cardiol; 2017 Mar; 40(3):163-169. PubMed ID: 27859433 [TBL] [Abstract][Full Text] [Related]
20. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease. Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]